Factors associated with prolonged viral shedding and impact of Lopinavir/Ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection

https://erj.ersjournals.com/content/early/2020/05/13/13993003.00799-2020

In a retrospective study of the 120 patients, 78 patients (65%) were administered with LPV/r treatment. The median duration of SARS-CoV-2 shedding in LPV/r treatment group was 22 days, which was significantly shorter than that in no LPV/r treatment group (28.5 days). Patients who initiated LPV/r treatment within 10 days from symptom onset had a shorter duration of SARS-CoV-2 RNA shedding compared with those without LPV/r treatment (median 19 days versus 28.5 days, log-rank p<0.001). In contrast, the median duration of viral shedding did not differ between patients who initiated LPV/r treatment >10 days from symptom onset and patients who did not receive LPV/r treatment (median 27.5 days versus 28.5 days.Earlier administration of LPV/r treatment may shorten the duration of SARS-CoV-2 RNA shedding.

 

 

Tags: